Back to Search

JOHN GOLAY, MD

MD

Family Medicine Physician

NPI: 1215944137IndividualAccepts Medicare

Specialties, Licenses & Credentials

Family Medicine PhysicianPrimary

Family Medicine

Code: 207Q00000X

9237(SC)

CMS Specialties

PrimaryFAMILY PRACTICE

Education

WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE

Class of 1977

Research & Publications (20)

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
PMID 19633847·Ann Hematol·2010
3-trial
M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
PMID 19299742·J Immunol·2009
8-other
Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
PMID 19375652·Exp Hematol·2009
8-other
The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs.
PMID 19462317·Cytotherapy·2009
8-other
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
PMID 18079739·Leukemia·2008
8-other
Chemokines and antagonists in non-Hodgkin's lymphoma.
PMID 18410244·Expert Opin Ther Targets·2008
6-review
FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
PMID 17650444·Haematologica·2007
4-observational
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
PMID 17637810·Leukemia·2007
7-preclinical
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.
PMID 17606446·Haematologica·2007
3-trial
The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab.
PMID 17475893·J Immunol·2007
7-preclinical
Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts.
PMID 17680021·Bone Marrow Transplant·2007
8-other
Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.
PMID 16980990·Bone Marrow Transplant·2006
8-other
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
PMID 16531255·Haematologica·2006
4-observational
The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
PMID 16461301·Haematologica·2006
7-preclinical
Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
PMID 15667532·Br J Haematol·2005
7-preclinical
Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines.
PMID 15449038·Cancer Immunol Immunother·2005
8-other
Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis.
PMID 14754610·Haematologica·2004
8-other
Effect of alemtuzumab on neoplastic B cells.
PMID 15590398·Haematologica·2004
4-observational
Innovative cell-based therapies in onco-hematology: what are the clinical facts ?
PMID 15477212·Haematologica·2004
6-review
From the bench to the bedside: ways to improve rituximab efficacy.
PMID 15226177·Blood·2004
6-review

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
811 WEST MAIN STREET, STE 207
LEXINGTON, SC 29072

Location

Practice Location

811 WEST MAIN STREET, LEXINGTON, SC
(803) 358-6420

Quick Facts

NPI
1215944137
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
1
Locations
1
Years in Practice
49
Publications
20

Are you this provider?

Claim Your Profile